Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis

Objective: This study aims to investigate the safety and efficacy of abrocitinib in treating moderate-to-severe AD in adolescents and adults. 

Methods: Pubmed, Cochrane, Embase, and Web of science data base were searched from inception to 9 August 2022. All randomized controlled trials (RCTs) evaluating the efficacy and safety of abrocitinib in moderate to severe AD were included in the meta-analysis. 

Results: This meta-analysis comprised 7 studies and found that 100 mg or 200 mg of abrocitinib significantly improved IGA {[RR = 2.44, 95% CI (1.93-3.08)] [RR = 3.16, 95% CI (2.52-3.96)]} and EASI-75{[RR = 2.18, 95%CI (1.78-2.67)] [RR = 3.04, 95%CI (2.22-4.16)]} responses compared to placebo. Following that, the population was divided into adolescent and adult groups. The abrocitinib improved IGA, EASI-75 responses, and it was still superior to placebo in both the adolescent and the adult groups. PP-NRS4 response index demonstrated that abrocitinib had a greater effect than placebo at 100 mg [RR = 2.22, 95% CI 1.80-2.72] and 200 mg [RR = 3.28, 95% CI 2.59-4.17]. Abrocitinib improved PSAAD, POEM, DLQI, CDLQI, and HADS more than a placebo. 

Conclusion: In conclusion, this meta-analysis preliminarily demonstrated that abrocitinib had higher efficacy and safety in the treatment of moderate-to-severe AD in adolescents and adults. In addition, abrocitinib could rapidly relieve itching, and effectively improve symptoms and signs, with a greater effect at the dosage of 200 mg than 100 mg.

 

Comments:

Your study aimed to investigate the safety and efficacy of abrocitinib in treating moderate-to-severe atopic dermatitis (AD) in both adolescents and adults. To conduct the study, you searched several databases including Pubmed, Cochrane, Embase, and Web of Science from inception to August 9, 2022. You included randomized controlled trials (RCTs) that evaluated the efficacy and safety of abrocitinib in moderate-to-severe AD for the meta-analysis.

The meta-analysis included a total of seven studies and found that both the 100 mg and 200 mg doses of abrocitinib significantly improved the Investigator's Global Assessment (IGA) and Eczema Area and Severity Index-75 (EASI-75) responses compared to placebo. The results were as follows:

- For IGA: The relative risk (RR) for improvement with abrocitinib compared to placebo was 2.44 (95% CI: 1.93-3.08) for the 100 mg dose and 3.16 (95% CI: 2.52-3.96) for the 200 mg dose.
- For EASI-75: The RR for improvement with abrocitinib compared to placebo was 2.18 (95% CI: 1.78-2.67) for the 100 mg dose and 3.04 (95% CI: 2.22-4.16) for the 200 mg dose.

After dividing the population into adolescent and adult groups, it was found that abrocitinib improved IGA and EASI-75 responses and remained superior to placebo in both groups. The study also assessed the Pruritus Numerical Rating Scale (PP-NRS4) response index, which demonstrated that abrocitinib had a greater effect than placebo at both the 100 mg and 200 mg doses:

- For 100 mg: RR = 2.22, 95% CI: 1.80-2.72.
- For 200 mg: RR = 3.28, 95% CI: 2.59-4.17.

Furthermore, abrocitinib was found to improve Patient-Reported Sleep and Activity Assessment in Atopic Dermatitis (PSAAD), Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), Children's Dermatology Life Quality Index (CDLQI), and Hospital Anxiety and Depression Scale (HADS) scores more effectively than placebo.

In conclusion, the meta-analysis provided preliminary evidence that abrocitinib is both safe and efficacious in treating moderate-to-severe AD in adolescents and adults. It was found to rapidly relieve itching and effectively improve symptoms and signs of AD. The 200 mg dose appeared to have a greater effect than the 100 mg dose.

Related Products

Cat.No.	Product Name	Information
S8765	Abrocitinib (PF-04965842)	Abrocitinib (PF-04965842) is a potent JAK1 inhibitor with IC50s of 29 nM, 803 nM, > 10 000 nM and 1250 nM for JAK1, JAK2, JAK3 and tyrosine kinase (TYK) 2, respectively.

Related Targets

JAK